Combinatorial chemistry and high-throughput screening in drug discovery and development

Separation Science and Technology

Volumn 3, Issue C, 2001, Pages 23-56

  Appell, Ken ^a   Baldwin, John J ^a   Egan, William J ^a  

^a Pharmacopoeia Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959571835     PISSN: 18771718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-6395(01)80004-0     Document Type: Chapter

References (173)

1. Dolle, R. E. Private communication, 1999.
2. Shaw, I. Scrip Magazine 6(July/August), 1999.
3. Lipper, R. A. E pluribus product. Modern Drug Disc. 2:55-60, 1999.
4. Johnson, D. The discovery-development Interface has become the new interfacial phenomenon. Drug Discovery Today 4:535-536, 1999.
5. Parlow J. J., Deuraj, R. V., and South, M. S. Solution-phase chemical Hbrary synthesis using polymer-assisted purification techniques. Curr. Opin. Chem. Biol. 3:320-336, 1999.
6. Suto, M. J. Developments in solution-phase combinatorial chemistry. Curr. Opin. Drug Disc. Dev. 2:377-384, 1999.
7. Dolle, R. E. and Nelson, K. H., Jr. Comprehensive survey of combinatorial library synthesis: 1998. J. Comb. Chem. 1:235-282, 1999.
8. Hermkens, P. H., Ottenheijm, H. C, and Rees, D. C. Solid-phase organic reactions: A review of the recent literature. Tetrahedon 52:4527-4554, 1996.
9. Hermkens, P. H., Ottenheijm, H. C, and Rees, D. C. Solid-phase organic reactions II: A review of recent literature Nov 95-Nov 96. Tetrahedon 53:5643-5678, 1997.
10. Booth, S., Hermkens, P. H., Ottenheijm, H. C , and Rees, D. C. Solid-phase organic reactions III: A review of the literature Nov 96-Dec 97. Tetrahedon 54:15, 385-15, 443, 1996.
11. Fruchtel, J. S. and Jung, G. Organic chemistry on solid supports. Angew. Chem., Int. Ed. Engl. 35:17-42, 1996.
12. Osborn, H. M. and Khan, T. H. Recent developments in polymer supported synthesis of oligosaccharides and glycopeptides. Tetrahedron 55:1807-1850, 1999.
13. Lorsbach, B. A. and Kurth, M. J. Carbon-carbon bond forming solid-phase reactions. Chem. Rev. 99:1549-1581, 1999.
14. Gordon, K. and Balasubramanian, S. Recent advances in soUd-phase chemical methodologies. Curr. Opin. Drug Disc. Dev. 2:342-349, 1999.
15. Furka, A., Sebestyen, E, Asgedom, M., and Dibo, G. In Proceedings of the 14th International Congress of Biochemistry, Vol. 5, p. 47 (abstract), de Gruyter, Berlin, 1989. In Proceedings of the 10th International Symposium on Medicinal Chemistry, p. 288 (abstract). Elsevier, Amsterdam, 1989.
16. Furka, A., Sebestyen, E, Asgedom, M., and Dibo, G. General method for rapid synthesis of multicomponent peptide mixtures. Int. J. Pept. Protein Res. 37:487-493, 1991.
17. Lam, K. S., Salmon, S. E., Hersh, E. M., Hruby, V. J., Kazmierski, W. M., and Knapp, R. J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354:82-84, 1991; errata 358:434, 1992; 360:768, 1992.
18. Dillard, L. W., Connelly, J. A., Baldwin, J. J., Horlbeck, E. G., Kirk, G. L., and Lauri, G. Selecting codes to be used for encoding combinatorial Libraries U.S. Patent 5, 663, 046, 1997.
19. Baldwin, J. J. and Dolle, R. E. Deconvolution tools for solid-phase synthesis. In A Practical Guide to Combinatorial Chemistry (A. W. Czarnick and S. H. DeWitt, Eds.), pp. 153-174. American Chemical Society, Washington, D.C., 1999.
20. Floyd, C. D., Leblanc, C, and Whittaker, M. Combinatorial chemistry as a tool for drug discovery. In Progress in Medicinal Chemistry (E D. King and A. W. Oxford, Eds.), Vol. 36, pp. 91-168. Elsevier Science, Amsterdam, Netherlands, 1999.
21. Brenner, S. and Lerner, R. Encoded combinatorial chemistry. Proc. Natl. Acad. Sci. U.S.A. 89:5381-5383, 1992.
22. Nielsen, J., Brenner, S., and janda, K. D. Synthetic methods for the implementation of encoded combinatorial chemistry. J. Am. Chem. Soc. 115:9812-9813, 1993.
23. Nikolaiev, V, Stierandova, A., Krchnak, V, Seligmann, B., Lam, K. S., Salmon, S. E., and Lebl, M. Peptide-encoding for structure determination of nonsequenceable polymers within Hbraries synthesized and tested on solid-phase supports. Pept. Res. 6:161-170, 1993.
24. Moran, E. J., Sarshar, S., Cargill, J. F., Shahbaz, M. M., Lio, A., Mjalli, A. M. M., and Armstrong, R. W. Radio frequency tag encoded combinatorial library method for the discovery of tripeptide-substituted cinnamic acid inhibitors of the protein tyrosine phosphatase PTPIB. J.Am. Chem. Soc. 117:10, 787-10, 788, 1995.
25. Nicolaou, K. C., Xiao, X. Y., Parandoosh, Z., Senyei, A., and Nova, M. P. Radiofrequency encoded combinatorial chemistry. Angew. Chem., Int. Ed. Engl. 34:2289-2291, 1995.
26. Frank, R. J. Simultaneous and combinatorial chemical synthesis techniques for the generation and screening of molecular diversity. J. Biotechnol. 41:259-272, 1995.
27. Houghten, R. A. General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. U.S.A. 82:5131-5135, 1985.
28. Terrett, N. K., Gardner, M., Gordon, D. W., Kobylecki, R. J., and Steele, J. Drug discovery by combinatorial chemistry-the development of a novel method for the rapid synthesis of single compounds. Chem.-Eur. J. 3:1917-1920, 1997.
29. Martin, E. J., Blaney, J. M., Siani, M. A., Spellmeyer, D. C., Wong, A. K., and Moos, W. H. Measuring diversity: Experimental design of combinatorial libraries for drug discovery. J.Med. Chem. 38:1431-1436, 1995.
30. Brown, R. D. and Martin, Y. C. Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection. J Chem. Inf. Comput. Sci. 36:572-584, 1996.
31. Chapman, D. The measurement of molecular diversity: A three-dimensional approach. J. Comput.-Aided Mol Des. 10:501-512, 1996.
32. Cramer, R. D., Clark, R. D., Patterson, D. E., and Ferguson, A. M. Bioisosterism as a molecular diversity descriptor: Steric fields of single "topomeric" conformers. J Med. Chem. 39:3060-3069, 1996.
33. Lipinski, C. A., Lombardo, E, Dominy, B. W., and Feeney, R J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 23:3-25, 1997.
34. Teague, S. J., Davis, A. M., Leeson, R D., and Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem., Int. Ed. Engl. 38:3743-3748, 1999.
35. Prentis, R. A., Lis, Y., and Walker, S. R. Pharmaceutical innovation by the seven UK-owmed pharmaceutical companies (1964-1985). Br.J. Clin. Pharmacol. 25:387-396, 1988.
36. DiMasi, J. A. Success rate for new drugs entering clinical testing in the United States. Clin. Pharmacol. Ther. 58:1-14.
37. Arlington, S. Pharma 2005-An industrial revolution in R&D. Pharm. Exec. Jan:74-84, 2000.
38. Navia, M. A. and Chaturvedi, P. R. Design principles for orally bioavailable drugs. Drug Discovery Today 1:179-189, 1996.
39. Chan, O. H. and Stewart, B. H. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discovery Today 1:461-473, 1996.
40. Smith, D. A., Jones, B. C , and Walker, D. K. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 16:243-266, 1996.
41. Sinko, P. J. Drug selection in early drug development: Screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr. Opin. Drug. Disc. Dev. 2:42-48, 1999.
42. Walters, W P., Ajay, and Murcko, M. A. Recognizing molecules with druglike properties. Curr. Opin. Chem. Biol. 3:384-387, 1999.
43. Lipper, R. A. E pluribus product. Modern Drug Disc. 2:55-60, 1999.
44. Tarbit, M. H. and Berman, J. High-throughput approaches for evaluating absorption, distribution, metabolism, and excretion properties of lead compounds. Curr. Opin. Chem. Biol. 2:411-416, 1998.
45. Lin, J. H. and Lu, A. Y. H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49:403-449, 1997.
46. Clark, D. E. and Pickett, S. D. Computational methods for the prediction of "drug-likeness." Drug Disc. Today 5:49-58, 2000.
47. Hirono, S., Nakagome, L, Hirano, H., Matsushita, Y, Yoshi, E, and Moriguchi, L. Noncongeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: Oral bioavailability. Biol. Pharm. Bull. 17:306-309, 1994.
48. Bemis, G. W. and Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J.Med. Chem. 39:2887-2893, 1996.
49. Bemis, G. W. and Murcko, M. A. Properties of known drugs. 2. Side chains. J Med. Chem. 42:5095-5099, 1999.
50. Lewell, X. Q., Judd, D. B., Watson, S. P., and Hann, M. M. RECAP-Retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci. 38;511-522, 1998.
51. Wang, J. and Ramnarayan, K. Toward designing drug-like libraries: A novel computational approach for the prediction of drug feasibility of compounds. J. Comb. Chem. 1:524-533, 1999.
52. Wagener, M. and van Geerestein, V. J. Potential drugs and nondrugs: Prediction and identification of important structural features. J. Chem. Inf. Comput. Sci. 40:280-292, 2000.
53. Sadowski, J. and Kubinyi, H. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 41:3325-3329, 1998.
54. Ajay, Walters, W. P., and Murcko, M. A. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?. J. Med. Chem. 41:3314-3324, 1998.
55. Ghose, A. K., Viswanadhan, V. N., and Wendoloski, J. J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1:55-68, 1999.
56. Oprea, T. I. Property distribution of drug-related chemical databses. J. Comput.-Aided Mol. Des. 14:251-264, 2000.
57. Conradi, R. A., Burton, P. S., and Borchardt, R. T. Physico-chemical and biological factors that influence a drug's cellular permeability by passive diffusion. Methods Prineiples Med. Chem. 4:233-252, 1996.
58. Camenisch, G., Folkers, and van de Waterbeemd, H. Review of theoretical passive drug absorption models: Historical background, recent developments and limitations. Pharm. Acta Helv. 71:309-327, 1996.
59. Kararli, T. T. Gastrointestinal absorption of drugs. Crit. Rev. Ther. Drugs Carrier Syst. 6:39-86, 1989.
60. Camenisch, G., Folkers, G., and van de Waterbeemd, H. Review of theoretical passive drug absorption models: Historical background, recent developments and limitations. Pharm. Acta Helv. 71:309-327, 1996.
61. Palm, K., Stenberg, P., Luthman, K., and Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14:568-571, 1997.
62. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 88:807-814, 1999.
63. Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C. , and Ploemen, J. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16:1514-1519, 1999.
64. Camenisch, G, Alsenz, J., van de Waterbeemd, H., and Folkers, G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 6:313-319, 1998.
65. Camenisch, G., Folkers, G., and van de Waterbeemd, H. Shape of membrane permeabilitylipophilicity curves: Extension of theoretical models with an aqueous pore pathway. Eur. J. Pharm. Sci. 6:321-329, 1998.
66. Wright, E. M. and Diamond, J. M. Patterns of non-electrolyte permeability. Proe. R. Soc. London, Ser. B 172:227-271, 1969.
67. Diamond, J. M. and Wright, E. M. Molecular forces governing non-electrolyte permeation through cell membranes. Proe. R. Soc. London, Ser. B 172:273-316, 1969.
68. van de Waterbeemd, H., Camenisch, G., Folkers, G., and Raevsky, O. A. Estimation of Caco-2 cell permeability using calculated molecular descriptors. Quant. Struet.-Act. Relat. 15:480-490, 1996.
69. Norinder, U., Osterberg, T., and Artursson, P. Theoretical calculation and prediction of Caco-2 cell permeability using molecular parametrization and PLS statistics. Pharm. Res. 14:1786-1791, 1997.
70. Norinder, U., Osterberg, T, and Artursson, P. Theoretical calculation and prediction of intestinal absorption of drugs in humans using molecular parametrization and PLS statistics. Eur.J. Pharm. Sci. 8:49-56, 1999.
71. Wessel, M. D., Jurs, P. C , Tolan, J. W., and Muskal, S. M. Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 38:726-735, 1998.
72. Winiwarter, S., Bonham, N. M., Ax, F., Hallberg, A., Lennernas, H., and Karlen, A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41:4939-4949, 1998.
73. Tsuji, A. and Tamai, I. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13:963-977, 1996.
74. Walter, E., Kissel, T., and Amidon, G. L. The intestinal peptide carrier: A potential transport system for small peptide derived drugs. Adv. Drug Delivery Rev. 20:33-58, 1996.
75. Swaan, P. W., Szoka, E C, Jr., and Oie, S. Use of the intestinal and hepatic bile acid transporters for drug delivery. Adv. Drug Delivery Rev. 20:59-82, 1996.
76. Swaan, P. W. and Tukker, J. J. Molecular determinants of recognition for the intestinal peptide carrier. J. Pharm. Sci. 86:596-602, 1997.
77. Bailey, P. D., Boyd, C. A. R., Bronk, J. R., Collier, I. D., Meredith, D., Morgan, K. M., and Temple, C. S. How to make drugs orally active: A substrate template for peptide transporter PepTl. Angew. Chem., Int. Ed. Engl. 39:506-508, 2000.
78. Swaan, P. W., Szoka, E C., Jr., and Oie, S. Molecular modeling of the intestinal bile acid carrier: A comparative molecular field analysis study. J. Comput.-Aided Mol. Des. 11:581-588, 1997.
79. Hunter, J. and Hirst, B. H. Intestinal secretion of drugs: The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Delivery Rev. 25:129-157, 1997.
80. Seelig, A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251:252-261, 1998.
81. Doeppenschmitt, S., Spahn-Langguth, H., Regrdh, C. G., and Langguth, P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88:1067-1072, 1999.
82. Hansch, C , Bjorkroth, J. P., and Leo, A. Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 76:683-686, 1987.
83. Pardridge, W. M. CNS drug design based in principles of blood-brain barrier transport. J.Neurochem. 70:1781-1792, 1998.
84. George, A. The design and molecular modeling of CNS drugs. Curr. Opin. Drug Disc. Dev. 2:286-292, 1999.
85. Levin, V. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:682-684, 1980.
86. 2 receptor histamine antagonists. J. Med. Chem. 31:656-671, 1988.
87. van de Waterbeemd, H. and Kansy, M. Hydrogen bonding capacity and brain penetration. Chimia 46:299-303, 1992.
88. Abraham, M. H., Chadha, H. S., and Mitchell, R. C. Hydrogen bonding. Part 33. Factors that influence the distribution of solutes between blood and brain. J. Pharm. Sci. 83:1257-1268, 1994.
89. Abraham, M. H., Chadha, H. S., and Mitchell, R. C. Hydrogen-bonding. Part 36. Determination of blood brain distribution using octanol-water partition coefficients. Drug Design Disc. 13:123-131, 1995.
90. Lombardo, E, Blake, J. F., and Curatolo, W. J. Computation of brain-blood partitioning of organic solutes via free energy calculations. J. Med. Chem. 39:4750-4755, 1996.
91. Norinder, U., Sjoberg, P., and Osterberg, T. Theoretical calculation and prediction of brainblood partitioning of organic solutes using molSurf parametrization and PLS statistics. J.Pharm. Sci. 87:952-959, 1998.
92. Luco, J. M. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least squares (PLS) modeling. J. Chem. Inf. Comput. Sci. 39:396-404, 1999.
93. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88:815-821, 1999.
94. Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C., and Ploemen, J. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16:1514-1519, 1999.
95. Vallner, J. J. Binding of drugs by albumin and plasma protein. J. Pharm. Sci. 66:447-465, 1977.
96. Oøie, S. Drug distribution and binding. J. Clin. Pharmacol. 26:586-5S6, 1986.
97. Rowley, M., Kulagowski, J. J., Watt, A. P., Rathbone, D., Stevenson, G. I., Carling, R. W., Baker, R., Marshall, G. R., Kemp, J. A., Foster, A. C., Grimwood, S., Hargreaves, R., Hurley, C., Saywell, K. L., Tricklebank, M. D., and Leeson, P. D. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J. Med. Chem. 40:4053-4068, 1997.
98. Moriguchi, I. Protein binding II. Binding of aromatic carboxylic acids to bovine serum albumin. Chem. Pharm. Bull. 16:597-600, 1968.
99. Biagi, G. L., Barbaro, A. M., Gandolfi, O., Guerra, M. C., and Cantelli-Forti, G. R. Values of steroids as an expression of their lipophilic character in structure-activity studies. J. Med. Chem. 18:873-883, 1975.
100. Jusko, W. J. and Gretch, M. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab. Rev. 5:43-140, 1976.
101. Seydel, J. K. and Schaper, K.-J. Quantitative structure-pharmacokinetic relationships and drug design. Pharmacol. Ther. 15:131-182, 1982.
102. Ritschel, W. A. and Hammer, G. V. Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption. Int. J. Clin. Pharmacol., Ther. Toxicol. 18:298-314, 1980.
103. Toon, S. and Rowland, M. Structure-pharmacokinetic relationships among the barbiturates in the rat. J. Pharmacol. Exp. Ther. 225:752-763, 1983.
104. Anton Fos, G. M., Garcia Domenech, R., Perez Gimenez, F., Galvez Alvarez, J., Garcia March, F., Soler Roca, R. M., and Salabert Salvador, M. T. Estudios de prediccion de propiedades farmacocineticas de hipoglucemiantes orales utilizando relacions Q.S.A.R. An. Real. Acad. Farm. 58:551-562, 1992.
105. Herman, R. A. and Veng-Pedersen, P. Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. J. Pharm. Sci. 83:423-428, 1994.
106. Hirono, S., Nakagome, I., Hirano, H., Yoshii, F., and Moriguchi, I. Noncongeneric Structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: Volume of distribution. Biol. Pharm. Bull. 17:686-690, 1994.
107. Moriguchi, I. Fuzzy adaptive least-squares and its use in QSAR. In Computer Aided Innovation of New Materials II. Proceedings of the International Conference on Exhibited and Computed Applied Materials, Molecular Science, and Engineering (M. Doyama, J. Kihara, M. Tanaka, and R. Yamamoto, Eds.), 2nd ed., pp. 1121-1126. North-Holland, Amsterdam, 1993.
108. Lázníček, M. and Láznícková, A. The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. J. Pharm. Biomed. Anal. 13:823-828, 1995.
109. Smith, D. R. Physicochemical properties in drug metabolism and pharmacokinetics. In Proceedings of the 11th European Symposium on Quantitative Structure-Activity Relationships (H. van de Waterbeemd, B. Testa, and G. Folkers, Eds.), pp. 267-276. Verlag Helvetica Chimica Acta, Basel, 1997.
110. Smith, D. A., Ackland, M. J., and Jones, B. C. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: Active site characteristics. Drug Discovery Today 2:406-414, 1997.
111. Smith, D. A., Ackland, M. J., and Jones, B. C. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates. Drug Discovery Today 2:479-486, 1997.
112. Ekins, S., Ring, B. J., Bravi, G., Wikel, J. H., and Wrighton, S. A. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millenium. In Pharmacophore Perception, Development, and Use in Drug Design (O. F. Güner, Ed.), pp. 269-299. International University Line, La Jolla, CA, 2000.
113. Lewis, D. F. V. In Proceedings of the 11th European Symposium on Quantitative Structure-Activity Relationships (H. van de Waterbeemd, B. Testa, and G. Folkers, Eds.), pp. 335-354. Verlag Helvetica Chimica Acta, Basel, 1997.
114. Strobl, G. R., von Kruedener, S., Stöckigt, J., Guengerich, F. P., and Wolff, T. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies. J. Med. Chem. 36:1136-1145, 1993.
115. Ekins, S., Bravi, G., Binkley, S., Gillespie, J. S., Ring, B. J., Wikel, J. H., and Wrighton, S. A. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 9:477-489, 1999.
116. de Groot, M. J., Ackland, M. J., Home, V. A., Alex, A. A., and Jones, B. C. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 42:1515-1524, 1999.
117. de Groot, M. J., Ackland, M. J., Home, V. A., Alex, A. A., and Jones, B. C. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 42:4062-4070, 1999.
118. Ekins, S., Bravi, G., Binkley, S., Gillespie, J. S., Ring, B. J., Wikel, J. H., and Wrighton, S. A. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J. Pharmacol. Exp. Ther. 290:429-438, 1999.
119. Ekins, S., Bravi, G., Wikel, J. H., and Wrighton, S. A. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J. Pharmacol. Exp. Ther. 291:424-433, 1999.
120. Fuhr, U., Strobl, G., Manaut, F., Anders, E., Sörgel, E, Lopez de Brinas, E., Chu, D. T. W., Pernet, A. G., Mahr, G., Sanz, F., and Staib, A. H. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol. Pharmacol. 43:191-199, 1993.
121. Ekins, S., Bravi, G., Ring, B. J., Gillespie, T. A., Gillespie, J. S., Vandenbranden, M., Wrighton, S. A., and Wikel, J. H. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J. Pharmacol. Exp. Ther. 288:21-29, 1999.
122. Jones, J. P., He, M., Trager, W. F., and Rettie, A. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab. Dispos. 24:1-6, 1996.
123. Rao, S., Aoyama, R., Schrag, M., Trager, W. F., Rettie, A., and Jones, J. P. A refined 3-dimensional QSAR of cytochrome P450 2C9: Computational predictions of drug interactions. J. Med. Chem. 43:2789-2796, 2000.
124. Kim, K. H. Quantitative structure-activity relationships of the metabolism of drugs by uridine diphosphonate glucuronosyltransferase. J. Pharm. Sci. 80:966-970, 1991.
125. Holmes, E., Sweatman, B. C., Bollard, M. E., Blackledge, C. A., Beddell, C. R., Wilson, I. D., Lindon, J. C., and Nicholson, J. K. Prediction of urinary sulphate and glucuronide conjugate excretion for substituted phenols in the rat using quantitative structure-metabolism relationships. Xenobiotica 25:1269-1281, 1995.
126. Cupid, B. C , Beddell, C. R., Lindon, J. C., Wilson, I. D., and Nicholson, J. K. Quantitative structure-metabolism relationships for substituted benzoic acids in the rabbit: Prediction of urinary excretion of glycine and glucuronide conjugates. Xenobiotica 26:157-176, 1996.
127. Hawkins, D. R. Use and value of metabolism databases. Drug Discovery Today 4:466-471, 1999.
128. Klopman, G., Dimayuga, M., and Talafous, J. META. 1. A program for the evaluation of metabolic transformation of chemicals. J. Chem. Inf. Comput. Sci. 34:1320-1325, 1994.
129. Talafous, J., Sayre, L. M., Mieyal, J. J., and Klopman, G. META. 2. A dictionary model of mammalian xenobiotic metabolism. J. Chem. Inf. Comput. Sci. 34:1326-1333, 1994.
130. Klopman, G., Tu, M., and Talafous, J. META. 3. A genetic algorithm for metabolic transform priorities optimization. J. Chem. Inf. Comput. Sci. 37:329-334, 1997.
131. Klopman, G., Tu, M., and Fan, B. T. META. 4. Prediction of the metabolism of polycyclic aromatic hydrocarbons. Theor. Chem. Acc. 102:33-38, 1999.
132. Smith, R. L. The Excretory Function of Bile. Chapman & Hall, London, 1973.
133. Hirom, P. C , Millburn, P., Smith, R. L., and Williams, R. T. Species variations in the threshold molecular-weight factor for the biUary excretion of organic anions. Biochem. J. 129:1071-1077, 1972.
134. Cantelli-Forti, G., Guerra, M. C., Barbaro, A. M., Hrelia, R, Biagi, G. L., and Borea, R A. Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats. J. Med. Chem. 29:555-561, 1986.
135. Fleck, C. and Braunlich, H. Factors determining the relationship between renal and hepatic excretion of xenobiotics. Arzneim.-Forsch. 40:942-946, 1990.
136. Shargel, L. and Yu, A. B. C. Applied Biopharmaceutics and Pharmacokinetics, 4th ed. Appleton & Lange, Stamford, CT, 1999.
137. Hamilton, H. W., Steinbaugh, B. A., Stewart, B. H., Chan, O. H., Schmid, H. L., Schroeder, R., Ryan, M. J., Keiser, J., Taylor, M. D., Blankley, C. J., Kaltenbronn, J. S., Wright, J., and Hicks, J. Evaluation of physicochemical parameters important to the oral bioavailability of peptide-like compounds: Implications for the synthesis of renin inhibitors. J. Med. Chem. 38:1446-1455, 1995.
138. Pitkin, D. H., Mico, B. A., Sitrin, R. D., and Nisbet, L. J. Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics. Antimicrob. Agents Chemother. 29:440-444, 1986.
139. Yamada, T. (RScD Chairman, SmithKline Beecham). The Pink Sheet-News from Europe Jan. 24, 2000.
140. Fisher, R. A. Statistical Methods for Research Workers. Oliver & Boyd, London, 1925; The Design of Experiments. Oliver &c Boyd, London, 1935.
141. Hunter, J. S. Applying statistics to solving chemical problems. CHEMTECH 17:167-169, 1987.
142. Czitrom, V. One-factor-at-a-time versus designed experiments. Am. Statist. 53:126-131, 1999.
143. Fecik, R. A., Frank, K. E., Gentry, E. J., Menon, S. R., Mitscher, L. A., and TelikepaUi, H. The search for orally active medications through combinatorial chemistry. Med. Res. Rev. 18:149-185, 1998.
144. Bohacek, R. S., McMartin, C., and Guida, W.C. The art and practice of structure-based drug design: A molecular modeling perspective. Med. Res. Rev. 16:3-50, 1996.
145. Walters, W. P., Stahl, M. T., and Murcko, M. A. Virtual screening-An overview. Drug Discovery Today 3:160-178, 1998.
146. Brennan, M. Drug discovery. Filtering out failures early in the game. Chem. Eng. News 78(23):63-73, 2000.
147. Bures, M. G. and Martin, Y. C. Computational methods in molecular diversity and combinatorial chemistry. Curr. Opin. Chem. Biol. 2:376-380, 1998.
148. Spellmeyer, D. C. and Grootenhuis, P. D. J. Recent developments in molecular diversity. Computational approaches to combinatorial chemistry. Annu. Rep. Med. Chem. 34:287-296, 1999.
149. Mason, J. S. and Hermsmeier, M. A. Diversity assessment. Curr. Opin. Chem. Biol. 3:342-349, 1999.
150. Hassan, M., Bielawski, J. P., Hempel, J. C , and Waldman, M. Optimization and visualization of molecular diversity of combinatorial libraries. Mol. Diversity 2:64-74, 1996.
151. Brown, R. D. and Martin, Y. C. Designing combinatorial library mixtures using a genetic algorithm. J. Med. Chem. 40:2304-2313, 1997.
152. Martin, E. J. and Critchlow, R. E. Beyond mere diversity: Tailoring combinatorial libraries for drug discovery. J. Comb. Chem. 1:32-45, 1999.
153. Gillet, V. J., Willett, P., Bradshaw, J., and Green, D. V. S. Selecting combinatorial Hbraries to optimize diversity and physical properties. J. Chem. Inf. Comput. Sci. 39:169-177, 1999.
154. Koehler, R. T, Dixon, S. L., and Villar, H. O. LASSOO: A generalized directed diversity approach to the design and enrichment of chemical libraries. J. Med. Chem. 42:4695-4704, 1999.
155. Jamois, E. A., Hassan, M., and Waldman, M. Evaluation of reagent-based and product-based strategies in the design of combinatorial library subsets. J. Chem. Inf. Comput. Sci. 40:63-70, 2000.
156. Gillet, V. J., Willett, P., and Bradshaw, J. The effectiveness of reactant pools for generating structurally-diverse combinatorial libraries. J. Chem. Inf. Comput. Sci. 37:731-740, 1997.
157. Ajay, Bemis, G. W., and Murcko, M.A. Designing libraries with CNS activity. J. Med. Chem. 42:4942-4951, 1999.
158. Martin, E. J., Critchlow, R. E., Spellmeyer, D. C., Rosenberg, S., Spear, K. L., and Blaney, J. M. Diverse approaches to combinatorial library design. Pharmacochem. Library 29:133-146, 1998.
159. Pickett, S. D., McLay, I. M., and Clark, D. E. Enhancing the hit-to-lead properties of lead optimization libraries. J. Chem. Inf. Comput. Sci. 40:263-272, 2000.
160. Egan, W. J., Merz, K. M., and Baldwrin, J. J. Qualitative prediction of drug absorption using multivariate statistics. Unpublished. J. Med. Chem. 43:3867-3877, 2000.
161. Johnson, D. The discovery-development interface has become the new interfacial phenomenon. Drug Discovery Today 4:535-536, 1999.
162. Stevens, M. E., Bouchard, P. J., Kariv, I., Chung, T. D., and Oldenburg, K. R. Comparison of automation equipment in high-throughput screening. J. Biomol. Screening 3:305-311, 1998.
163. Dunn, D., Orlowski, M., McCoy, R., Gastgeb, E., Appell, K., Ozgur, L., Webb, M., and Burbaum, J. Ultra-high throughput screen of two-million-member combinatorial compound collection in a miniaturized, 1536-well format. J. Biomol. Screening 5:177-187, 2000.
164. Wang, G. T., Matayoshi, E., Huffaker, J. E., and Krafft, G. A. Design and synthesis of new fluorogenic HIV protease substrates based on resonance energy transfer. Tetrahedron Lett. 31:6493-6496, 1991.
165. Burbaum, J. J. Miniaturization technologies in HTS: How fast, how small how soon? Drug Discovery Today 3:313-322, 1998.
166. Earnshaw, D. L., Moore, K. J., Greenwood, C. J., Djaballah, H., Jurewicz, A. J., Murray, K. J., and Pope, A. J. Time-resolved fluorescence energy transfer DNA heHcase assays for high-throughput screening. J. Biomol. Screening 4:239-248, 1999.
167. Wu, J., Yarwood, D. R., Pham, Q., and Sills, M. A. Identification of a high-affinity antiphosphoserine antibody for the development of a homogeneous fluorescence polarization assay of protein kinase C. J. Biomol. Screening 5:23-30, 2000.
168. Levine, L. M., Michener, M. L., Toth, M. V., and Holwerda, B. C. Measurement of specific protease activity utilizing fluorescence polarization. Anal. Biochem. 247:83-88, 1997.
169. Banks, P., Gosselin, M., and Prystay, L., Fluorescence polarization assays for high-throughput screening of G protein-coupled receptors. J. Biomol. Screening 5:159-167, 2000.
170. Miragha, S., Swartzman, E. E., Mellentin-Michelotti, J., Evangelista, L., Smith, C., Gunawan, I., Lohman, K., Goldberg, E. M., Manian, B., and Yuan, P. Homogeneous cell- and bead-based assays for high-throughput screening using fluorometric microvolume assay technology. J. Biomol. Screening 4:193-204, 1999.
171. Ohhneyer, M. H. J., Swanson, R. N., Dillard, L. W., Reader, J. C., Asouline, G., Kobayashi, R., Wigler, M., and Still, W C. Complex synthetic chemical libraries indexed with molecular tags. Proc. Natl. Acad. Sci. U.S.A. 90:10, 922-10, 926, 1993.
172. Nestler, H. P., Bartlett, P. A., and Still, W. C. A general method for molecular tagging of encoded combinatorial chemistry libraries. J. Org. Chem. 59:4723-4724, 1994.
173. Horlick R. A., Ohlmeyer, M. H., Stroke, I. L., Strohl, B., Pan, G., Schilling, A. E., Paradkar, v., Quintero, J. G., You, M., Riviello, C , Thorn, M. B., Damaj, B., Fitzpatrick, V. D., DoUe, R. E., Webb, M. L., Baldwin, J. J., and Sigal, N. H. Small molecule antagonists of the bradykinin Bl receptor. Immunopharmacology 43:169-177, 1999.